INTRODUCTION
It was planned to design the formulation in such a way that it provides the delivery of drug at a controlled rate across intact human skin to achieve a therapeutic effective drug level for a longer period of time. The polymeric monolithic matrix type transdermal films are widely used to provide controlled delivery of drug substances because of their versatility, effectiveness, and low cost. These types of systems are also suitable for inhouse development because they are usually manufactured using conventional equipment and processing. The benefits of using transdermal drug delivery include improved systemic bioavailability resulting from bypassing the first hepatic metabolism. Variables due to oral administration, such as pH, the presence of food or enzymes, and transit times can all be eliminated. The aim in the development of new transdermal drug delivery device is to obtain a controlled, predictable, and reproducible release of the drug into the blood stream of the patient. 1, 2 The first and most important parameter for the development of a polymeric film is the choice of polymer. Besides having good film-forming properties and being a non-skin-irritant, the polymer must be soluble in a skin-tolerant solvent. The investigated polymers comprised combination of polymersAmmonio Methacrylate Copolymers such as Eudragit RLPO (ERLPO) and Eudragit RSPO (ERSPO) with hydrophilic polymer Methocel K15M (MK15M) and combination of polymers such as Methacrylic acid copolymers Acrylcoat L100 (AL100) and Acrylcoat S100 (AS100) with hydrophilic polymer MK15M. A great effort has been devoted to optimize the innovated films as far as possible. However, optimal properties cannot be achieved for a single polymer. Therefore, blending of polymers is necessary to attain more suitable transdermal devices regarding properties and performance. These transdermal delivery systems are neither extremely hydrophobic nor extremely hydrophilic. Binary blends of MK15M and the different types of Ammonio Methacrylate Copolymers & Methacrylic acid copolymers in different concentration were done to ameliorate physicochemical properties and to optimize performance. Beside the other components of transdermal patches, plasticizers also significantly change the viscoelastic properties of the polymers by the improvement of film forming properties and the appearance of the film, preventing film cracking, increasing film flexibility and obtaining desirable mechanical properties. The plasticizers tried in optimization trials were lipophilic plasticizers Dibutyl Phathalate (DBP) & Dibutyl Sebacate (DBS) and hydrophilic plasticizers Polyethylene glycol 400 (PEG 400) & Propylene Glycol (PG). In this research work, 2 different permeation enhancers of Terpene class such as d-limonene and 1,8 cineole were used. They were used in combinations so that more effective and enhanced transdermal drug transport can be obtained by synergism and it's also safe as the strength of individual enhancers can be reduced without compromising on drug release.
Drug of choice Monolithic matrix transdermal therapeutic systems is Metoprolol Tartrate. Metoprolol tartrate is prferred because of its relative β-1 selectivity, it is safe for use in patients with bronchospastic disease. Metoprolol tartrate has a oral bioavailability of only 38 % due to extensive hepatic first-pass metabolism. The half-life of the Metoprolol is about 3.2 hours, which makes frequent dosing necessary to maintain the therapeutic blood levels of the drug for long-term treatment. [3] [4] [5] [6] [7] .5:2.5 w/w %) was added to each polymer combination. The resulting solution (10 ml) was poured in a petri dish of 9.2 cm diameter containing mercury. The rate of evaporation of the solvent was controlled by placing an inverted funnel over the petri dish and allowed for drying over night followed by vacuum drying. The film formation was noted by observing the mercury surface after complete evaporation of the solvent. Aluminium foil was used as backing film and wax paper as release liner (which could be removed before application of the patch on the skin) were applied to complete the TDDS. The patches were cut with a circular metallic die of 2 cm internal diameter to give an area of 3.14 cm 2 and stored in a desiccator until use. 
MATERIAL AND METHODS

Materials
EVALUATION OF FORMULATIONS:
Physico-chemical evaluation
The Physico-chemical properties of patches are among the factors, which determine the suitability and acceptability of the prepared patches. The thickness, weight, drug content, tensile strength, % elongation, folding endurance, flatness % absorption and % loss, swelling and pH were determined for the prepared patches. Physicochemical evaluation and appropriate quality control are essential to ensure safety and adequate performance of designed formulae.
Physical appearance of formed films
All the prepared patches were visually inspected for color, clarity, flexibility and smoothness.
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Uniformity of Thickness
The thicknesses of the drug-loaded polymeric films were measured at three different points using a digital micrometer (Mitutoyo, Japan). The average and standard deviation of three readings were calculated for each batch of the drug-loaded films.
11,12
Uniformity of weight A specified area (1 cm   2 ) of patch is to be cut in different parts of the patch and is to be dried at 60°c for 4hrs before testing and Weight variation is studied by individually weighing 03 randomly selected patches and calculating the average weight. The individual weight should not deviate significantly from the average weight.
13,14
Uniformity of Drug content
An accurately weighed portion of patch was placed in 100 ml of 7.4 phosphate buffer and then the solution was shaken continuously for 24 hrs in shaker incubator. Then the whole solution was sonicated for complete extraction of drug from the patch. After incubation and subsequent filtration, drug in solution was estimated against the reference solution consisting of placebo films (contains no drug) with UV spectrophotometry at 274 nm. 15, 16 Surface pH Surface pH of the patches was determined by the m ethod described by Bottenberg et al. The patches were allowed to swell by keeping them in co ntact with 0.5 ml of double distilled water for 1 hour i n glass tubes. The surface pH was then noted by bringing acombined glass electrode near the surface of the patch and allowing it to equilibrate for 1 minute. 17 
Flatness
A transdermal patch should possess a smooth surface and should not constrict with time. This can be demonstrated with flatness study. For flatness determination, one strip is cut from the centre and two from each side of patches. The length of each strip is measured and variation in length is measured by determining percent constriction. 0% constriction is equivalent to 100 % flatness. 
Tensile Strength
Tensile strength of the film was determined with Universal Strength Testing Machine. The sensitivity of the machine was 1 g. It consisted of two load cell grips. The lower one was fixed and upper one was movable. The test film of size (4×1cm 2 ) was fixed between these cell grips and force was gradually applied till the film broke. Tensile strength is expressed as follows 19, 20 Percentage elongation break test
The percentage elongation break is determined by noting the length just before the break point, the percentage elongation can be determined from the below mentioned formula 21 Where, L 1 is the final length of each strip and L 2 is the initial length of each strip.
Folding endurance
Evaluation of folding endurance involves determining the folding capacity of the films subjected to frequent extreme conditions of folding. Folding endurance is determined by repeatedly folding the film at the same place until it break; the number of times the films could be folded at the same place without breaking is folding endurance value.
22
Percentage moisture absorption
Initial weight of the patch was taken and noted, then weighed patch are kept in desiccators at room temperature for 24 h. These are then taken out and exposed to 75% relative humidity using saturated solution of sodium chloride in desiccators until a constant weight is achieved. Final weight of the patch was calculated and percentage moisture uptake is calculated as given below.
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Percentage moisture loss
The prepared patch are weighed individually and kept in a desiccators containing fused calcium chloride at room temperature for 24 h. The patch is weighed again after a specified interval until they show a constant weight. The percent moisture content is calculated using following formula: 24 
Swelling Studies
Weight increase due to swelling was measured. The drug-loaded patch of size 1 x 1 cm 2 was weighed on a pre-weighed cover slip. It was kept in a petridish and 50 ml of phosphate buffer (pH 7.4) solution was added. After every five min, the cover slip was removed, wiped with tissue paper, and weighed upto 30 min. The difference in the weights gives the weight increase due to absorption of water and swelling of patch. 25, 26 The percent swelling, %S was calculated using the following equation;
Where Xt is the weight of the swollen patch after time t and Xo is the original patch weight at zero time.
RESULT AND DISCUSSION
Physico-chemical Evaluation of Formulations
Physical appearance of formed films
All the patches prepared with different polymer concentration were found to be flexible, translucent, hard and homogeneous in nature.
Uniformity of Thickness
Transdermal patches were transparent, smooth, uniform and flexible. The thickness of the weights ranged between 0.179±0.0051 to 0.258±0.0063 formulations (EM1 to EM8 and AM1 to AM8). The result indicated that there was no much difference in the thickness within the formulations. Low standard deviation and % Relative standard deviation values in the film thickness measurements ensured uniformity of the films prepared by solvent evaporation method. If we compare among different polymer combination we found that as the proportion of Ammonio Methacrylate Copolymers or Methacrylic acid co-polymers was increased or as the proportion of MK15M was decreased, the thickness decreases. The uniformity of thickness of the formulation EM1-EM8 and AM1-AM8 were shown in 
Uniformity of Drug content
Homogeneous uniform drug distribution is one of the important characteristics of a transdermal patch that ensures the uniform reproducible sustained release of the drug from the patch. The drug content (%) of all the formulations was found to be more than 90%. The results of content uniformity indicated that the drug was uniformly dispersed. The results of content uniformity indicated that the drug was uniformly dispersed. Recovery was possible to the tune of 94.43±1.33 to 95.77±0.83 for formulations EM1 to EM8 and 94.20±1.25 to 96.33±±1.14 for formulations AM1 to AM8. The uniformity of drug content of the formulation EM1-EM8 are shown in 
Surface pH
The surface pH of all the formulations was in th e range of 5.2±0.154 to 5.90±0.145 (EM1 to EM8 and AM1 to AM8), these values are close to the pH range of skin (4.5-5.5) 1 and hence no skin irritation was expected.
The surface pH of the formulations EM1-EM8 and AM1 to AM8) are shown in 
Percentage Elongation at break
The % elongation at break gives an indication of the elasticity of the film. An inverse relation was observed between tensile strength and elongation at break. The % Elongation at break of all the formulations was in the range of 71.22±1.44 % to 86.31±1.82 % (EM1 to EM8 and AM1 to AM8). Elongation at break test (%) results showed that the patch contains Methocel K15M in higher amount were more strengthens. There is increase in % elongation at break with decrease in Ammonio Methacrylate Copolymers or Methacrylic acid co-polymers in the polymer blend. The % elongation at break of the formulation EM1-EM8 and AM1-AM8 are shown in 
Percentage moisture absorption
The physicochemical studies like moisture loss and moisture uptake provide the information regarding the stability of the formulation. The % moisture uptake of the transdermal formulations was also low, which protect the film from microbial contamination as well as bulkiness of transdermal patch. The moisture absorption of all the formulations was in the range of 4.6 ±0.109 % to 6.70±0.125 % (EM1 to EM8 and AM1 to AM8). The % Moisture absorption of the formulation EM1-EM8 and AM1-AM8 are shown in 
Percentage moisture loss
The % moisture loss of the prepared transdermal film was low, which maintains suppleness, thus preventing drying and brittleness. The moisture content of all the formulations was in the range of 2.50±0.081 % to 3.80±0.088% (EM1 to EM8 and AM1 to AM8). Generally, the moisture uptake capacity of films increases with increasing hydrophilicity of the polymer or plasticizer. The formulations containing higher proportion of hydrophilic polymer Methocel K15M shows significant moisture absorption and moisture loss when compare to other patches having lower proportion of Methocel K15M. The moisture content of the Eudragit RLPO and Methocel K15M combination patches was higher compared to Eudragit RSPO and Methocel K15M combination patches due to relatively more hydrophobic nature of Eudragit RSPO than Eudragit RLPO. The % Moisture loss of the formulation EM1-EM8 and AM1-AM8 are shown in 
Swelling Studies
Percentage swelling varied between 11.15±0.31 to 20.65±0.56 % (EM1 to EM8 and AM1 to AM8) for different polymeric patches. Hydrophilic polymers showed considerable swelling, as it increased the surface wettability and consequently water penetration within the matrix. The formulations containing higher proportion of hydrophilic polymer MK15M shows significant swellability when compare to other patches having lower proportion of MK15M. The % swellability of the ERLPO and MK15M combination patches was higher compared to ERSPO and MK15M combination patches due to relatively more hydrophobic nature of ERSPO than ERLPO. The % Swelling of the formulation EM1-EM8 and AM1-AM8 are shown in 
